Literature DB >> 24001291

Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians.

Perrine Roux, Caroline Lions, Laurent Michel, Julien Cohen, Marion Mora, Fabienne Marcellin, Bruno Spire, Alain Morel, Patrizia M Carrieri, Laurent Karila.   

Abstract

BACKGROUND: Although methadone maintenance treatment (MMT) is recognized as the treatment of reference for opioid dependence, little information is available regarding the dynamic adherence to methadone and its determinants. With data from the Methaville trial we investigated the evolution of non-adherence to methadone and the effect of pre-treatment and in-treatment factors on longterm non-adherence to methadone.
METHODS: We selected 145 patients to study adherence to methadone at 3, 6 and 12 months (M3, M6 and M12, respectively) using a multidimensional questionnaire and a 3-level variable "adherent"/"non adherent"/"highly nonadherent". We then identified the pre-treatment and in-treatment variables associated with long-term non-adherence to methadone at the M12 visit using a univariate logistic regression and two different multivariate models: the first incorporating only the pre-treatment variables, the second adding the in-treatment variables to the pre-treatment ones.
RESULTS: At the M12 visit, 35.2% of the participants remained adherent, 55.9% and 9% were non-adherent and highly non-adherent, respectively. The multivariate analysis of long-term non-adherence to methadone showed 4 pre-treatment predictors and 1 in-treatment predictor as follows: being female, not having stable housing, alcohol consumption, cocaine use and perceiving methadone dose as inadequate.
CONCLUSIONS: Our findings highlight that pretreatment predictors are important to consider when starting maintenance treatment for opioid dependence, such as cocaine use and problematic alcohol consumption but also low socio-economic levels. In addition, during maintenance treatment, in-treatment predictors such as methadone dose adequacy is a crucial issue to achieve good adherence to MMT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24001291     DOI: 10.2174/13816128113199990623

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  23 in total

1.  High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.

Authors:  Maria Eugenia Socías; Evan Wood; Stephanie Lake; Seonaid Nolan; Nadia Fairbairn; Kanna Hayashi; Hennady P Shulha; Seagle Liu; Thomas Kerr; M-J Milloy
Journal:  Addiction       Date:  2018-09-20       Impact factor: 6.526

2.  Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations.

Authors:  Joan Trujols; M Josefa Campins; Elisa Ribalta
Journal:  CMAJ       Date:  2019-09-30       Impact factor: 8.262

3.  Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.

Authors:  Andreea A Artenie; Nanor Minoyan; Brendan Jacka; Stine Høj; Didier Jutras-Aswad; Élise Roy; Lise Gauvin; Geng Zang; Julie Bruneau
Journal:  CMAJ       Date:  2019-04-29       Impact factor: 8.262

4.  Opioid Misuse as a Predictor of Alcohol Treatment Outcomes in the COMBINE Study: Mediation by Medication Adherence.

Authors:  Katie Witkiewitz; Victoria R Votaw; Kevin E Vowles; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2018-06-09       Impact factor: 3.455

5.  Defining and Predicting Opioid and Cocaine Treatment Response.

Authors:  Robert A Gardner; David H Epstein; Kenzie L Preston; Karran A Phillips
Journal:  Subst Use Misuse       Date:  2019-07-18       Impact factor: 2.164

6.  Alcohol use disorder and motives for prescription opioid misuse: A latent class analysis.

Authors:  Victoria R Votaw; R Kathryn McHugh; Katie Witkiewitz
Journal:  Subst Use Misuse       Date:  2019-05-07       Impact factor: 2.164

7.  Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.

Authors:  Dana Button; Ryan Cook; Caroline King; Tong Thi Khuyen; Lynn Kunkel; Gavin Bart; Dinh Thanh Thuy; Diep Bich Nguyen; Christopher K Blazes; Le Minh Giang; P Todd Korthuis
Journal:  Int J Drug Policy       Date:  2021-11-09

8.  Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.

Authors:  Ada Lo; Thomas Kerr; Kanna Hayashi; M-J Milloy; Ekaterina Nosova; Yang Liu; Nadia Fairbairn
Journal:  J Subst Abuse Treat       Date:  2018-08-23

9.  The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use disorder treatment outcomes following release from jail.

Authors:  Benjamin A Howell; Lisa Puglisi; Katie Clark; Carmen Albizu-Garcia; Evan Ashkin; Tyler Booth; Lauren Brinkley-Rubinstein; David A Fiellin; Aaron D Fox; Kathleen F Maurer; Hsiu-Ju Lin; Kathryn McCollister; Sean Murphy; Diane S Morse; Shira Shavit; Karen Wang; Tyler Winkelman; Emily A Wang
Journal:  J Subst Abuse Treat       Date:  2021-01-29

10.  Antinociceptive effect of clavulanic acid and its preventive activity against development of morphine tolerance and dependence in animal models.

Authors:  V Hajhashemi; Kh Dehdashti
Journal:  Res Pharm Sci       Date:  2014 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.